Pfizer announces positive top-line results from JADE TEEN trial of abrocitinib in adolescents with moderate-to-severe atopic dermatitis

In study (n=285) of this oral JAK-1 inhibitor, both doses of abrocitinib met co-primary endpoints at week 12 of proportion of patients who achieved IGA of clear (0) or almost clear (1) and ≥2-point reduction from baseline; and who achieved ≥75% change from baseline in EASI score.


Biospace Inc.